- Home
- Products
Balversa (Erdafitinib)
Balversa (Erdafitinib)
Medicine Name: Balversa
Generic Name: Erdafitinib
Dosage Form & Strength: Tablets – 3 mg, 4 mg, 5 mg
Manufactured By: Janssen Pharmaceuticals, Inc.
Balversa is a kinase inhibitor approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with:
- FGFR2/3 genetic alterations, and
- Disease progression during or after at least one line of platinum-containing chemotherapy (including neoadjuvant/adjuvant within 12 months)
Recommended Dosage:
- Start with 8 mg orally once daily (2 × 4 mg tablets)
- Increase to 9 mg daily (3 × 3 mg tablets) based on phosphate levels and tolerability after 2–3 weeks
- Swallow tablets whole, with or without food
- If vomiting occurs, do not retake; continue with the next scheduled dose
- Do not double the dose if one is missed
Ocular Toxicity (CSR/RPED): Can lead to visual defects. Monthly eye exams for first 4 months, then quarterly. Immediate assessment for visual symptoms
Hyperphosphatemia: Monitor phosphate levels regularly and modify dose as per protocol
Fetal Harm: Erdafitinib may harm an unborn baby. Use effective contraception during treatment and for 1 month after the last dose
Breastfeeding: Avoid during and for 30 days after final dose due to potential serious adverse effects in nursing infants
Documents Required to Import Balversa to India:
- Prescription from a qualified physician
- Diagnostic reports
- Government-issued photo ID
Order Confirmation:
- Confirmed after receipt of all documentation and import permit (if applicable)
Availability in India & Internationally: Available through Global Rare Meds in India – Mumbai, Delhi, Chennai, Hyderabad, Bangalore, Kolkata, Ahmedabad, Pune, and other major cities. Also available for export to eligible countries under the named patient program.
To Order or Enquire Price:
- Phone/WhatsApp: +91-99675 15602
- Email: info@globalraremeds.com
Global Rare Meds sources Balversa from certified suppliers in the USA, Europe, Canada, and Australia. Every prescription is validated by licensed pharmacists and securely dispatched from our fulfillment center in Ambernath, Thane District.
We ensure legal compliance, quality assurance, and reliable international delivery.
What is the generic name of Balversa®?
Erdafitinib
Who manufactures Balversa®?
Janssen Pharmaceuticals, Inc.
Is Balversa® FDA approved?
Yes, approved on April 12, 2019
What dosage forms are available?
Tablets: 3 mg, 4 mg, 5 mg
What are common side effects of Balversa®?
Mouth sores, fatigue, diarrhea, dry mouth, changes in liver function, low sodium, decreased appetite, altered taste, anemia, dry skin/eyes, hair loss, constipation, abdominal pain, nausea, muscle pain
What is the price of Balversa® in India?
Prices vary. For current pricing, contact us via WhatsApp at +91-99675 15602 or email info@globalraremeds.com
How should Balversa® be stored?
Store at 20°C to 25°C (68°F to 77°F), excursions allowed between 15°C and 30°C (59°F to 86°F)
Can I order Balversa® online from India?
Yes, Global Rare Meds facilitates legal access through the named patient import program
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
